This non-foolish comprehensive cannabis-reform bill would remove cannabis from scheduled drug classification under the Controlled Substance Act, expunge previous cannabis-related convictions, and establish a federal tax rate on all cannabis products in the states.
Essentially, under the MORE Act, all cannabis products could .
The history of the FDA dates to the 1906 Food and Drug Act and essentially morphed into the 1938 Food, Drug and Cosmetic Act, which the agency still operates under today.
For example, under the FDA’s Center for Tobacco Products, all new tobacco products that enter the market after 2007 must undergo an extensive approval process to even market their products.
In fact, some studies have shown that bringing a new drug to market can cost more than $1 billion and take more than a decade.
The Center for Food Safety and Applied Nutrition is the FDA branch that oversees about 78 percent of the food consumed by Americans.
These are just a few snippets of the massive authority FDA already has over consumer products and the costs associated with FDA-created regulations.
In 2009, the FDA tried to block shipments of e-cigarettes to the U.S, using their CDER regulatory authority, and was promptly sued by e-cigarette manufacturers.
In 2016, the FDA established the long-awaited deeming regulations, codifying federal regulations for novel tobacco products, including any that had entered the market after February 15, 2007 – or two years prior to FDA regulatory authority over tobacco products.
As noted, the FDA has not been the best federal agency in empowering small businesses.
Thankfully, the MORE Act isn’t the only comprehensive cannabis reform bill before Congress.